Calcium Channel Blockers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Calcium Channel Blockers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • Transparency Market Research
  • Ongoing
  • Pharmaceutical

Report Description

Cardiovascular diseases is one of the major causes of death across the globe. According to the World Health Organization, the number of deaths caused by these diseases is expected to reach over 23 million by 2030. These are largely lifestyle diseases and about 16% of deaths caused by these diseases in 2012 were attributed to high blood pressure. Various classes of drugs used to treat cardiac disorders include calcium channel blockers, anti-adrenergic agents, anti-arrhythmic agents, diuretic agents, and angiotensin-converting enzyme (ACE) inhibitors. Calcium channel blockers, alternatively known as calcium channel antagonists, are widely used to treat conditions such as hypertension, angina, arrhythmia, and other cardiac diseases. Calcium channels play an important role in controlling the influx of calcium (Ca+) into muscle cells. This influx of calcium into the muscle cells results into stimulation of smooth muscle contraction along with cardiac myocyte contraction. Hence, by blocking entry of calcium ions into the cell, calcium channel blockers cause vasodilation (vascular smooth muscle relaxation), decreased heart rate, decreased myocardial force generation, and decreased conduction velocity within the heart.

Calcium channel blockers act by dilating blood vessels, thereby increasing the blood flow which reduces blood pressure. Despite their effectiveness, prolonged usage of calcium channel blockers often leads to high mortality rate and multiple side effects such as dizziness, constipation, swelling of feet and ankles, sexual dysfunction, gastroesophageal reflux disease, and bleeding of gums. Some of the prominent calcium channel blockers include Norvasc (amlodipine), Plendil (Felodipine), Cardizem (diltiazem), Adalat (nifedipine), Cardene (nicardipine), Vascor (bepridil), Dilacor XR (diltiazem), Dynacirc (Isradipine), and Verelan (Verapamil). Increase in prevalence of cardiac diseases and other conditions such as hypertension, angina, and arrhythmia are the major drivers of the global calcium channel blockers market. However, side effects associated with the prolonged use of calcium channel blockers restrain the market.

The global calcium channel blockers market can be segmented based on type, application, distribution channel, and region. In terms of type, the market can be classified into dihydropyridines, benzothiazepines (diltiazem), and phenylalkylamines (verapamil). These three types of calcium channel blockers differ in their chemical structure and mechanism of action. Dihydropyridines include drugs such as amlodipine, isradipine, nitrendipine, felodipine, nimodipine, and nicardipine. Based on application, the global calcium channel blockers market can be categorized into hypertension, arrhythmia, and angina. In terms of distribution channel, the market can be divided into hospital pharmacies, clinics, retail pharmacies, and online pharmacies.

In terms of region, the global calcium channel blockers market can be segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. Advancement in drug discovery and research technology is anticipated to boost the calcium channel blockers market during the forecast period. Various government initiatives and funding are also likely to augment the calcium channel blockers market. Moreover, awareness about drugs and their availability in different parts of the world fuels the growth of the market. Large population and increased prevalence of cardiac diseases in Asia Pacific is attributed to strong growth of the global calcium channel blockers market during the forecast period. The market is likely to also to witness moderate growth in Middle East & Africa and Latin America.

Key players of the global calcium channel blockers market include Novartis AG, Pfizer, Inc., Johnson & Johnson Ltd., Sanofi S.A, Daiichi Sankyo Company Limited, AstraZeneca plc, Merck & Co., Ranbaxy Laboratories Limited, and Lupin Limited.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market       

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Have query on this report?

Make an Enquiry

Success Stories

Our Clients